Mineralys Therapeutics presented new clinical trial data for lorundrostat, its investigational aldosterone synthase inhibitor for treating difficult-to-treat hypertension. The Launch-HTN trial showed 46% of participants achieved AHA/ACC guideline systolic blood pressure targets (<130 mmHg) at 12 weeks, with over two-thirds achieving ≥10 mmHg reduction. The Explore-OSA trial demonstrated clinically meaningful morning blood pressure reductions in obstructive sleep apnea patients with no adverse effects on sleep apnea indices.

Mineralys Therapeutics announced that new data from the Launch-HTN Phase 3 clinical trial of lorundrostat, an investigational aldosterone synthase inhibitor, will be presented at the American Society of Nephrology Kidney Week 2026. The presentation will focus on blood pressure and albuminuria reduction in chronic kidney disease patients. Lorundrostat is being developed to treat uncontrolled and resistant hypertension, with the company having completed six late-stage clinical trials demonstrating efficacy and safety.

Over 100 pharmaceutical companies are actively developing 110+ pipeline hypertension drugs, with approximately 40+ in late-stage development. Key players include Gossamer Bio, Alnylam Therapeutics, Roche, GSK, and others pursuing novel mechanisms like RNA interference and CRAC channel inhibitors. Recent developments include FDA acceptance of lorundrostat's NDA, initiation of zilebesiran's Phase III cardiovascular outcomes trial, and multiple clinical advances in emerging therapies targeting uncontrolled and resistant hypertension.

Mineralys Therapeutics announced that late-breaking data from a proteomic analysis of heart failure biomarkers during lorundrostat treatment will be presented at ENDO 2026. The data comes from post hoc analysis of the Launch-HTN and Advance-HTN trials, which evaluated the aldosterone synthase inhibitor for treating uncontrolled and resistant hypertension.

Mineralys Therapeutics announced the repurchase of all future royalty payments to Tanabe Pharma for lorundrostat, paying $200 million upfront plus up to $100 million upon commercial milestones. Concurrently, the company secured a $500 million senior secured term loan facility from Pharmakon Advisors and priced a $150 million common stock offering to strengthen its balance sheet.

Velan Capital Investment Management LP sold 140,000 shares of Mineralys Therapeutics in Q1 2026, valued at approximately $4.11 million, reducing its stake to 11,000 shares. Despite the fund's reduction, Mineralys stock has surged 87.84% over the past year. The clinical-stage biotech company is awaiting FDA approval for its lead candidate lorundrostat by December 22, 2026, and maintains $646 million in cash.

Mineralys Therapeutics presented post hoc analysis data from its Phase 3 Launch-HTN trial showing that lorundrostat, an aldosterone synthase inhibitor, achieved statistically significant blood pressure reductions in patients with chronic kidney disease (CKD) and hypertension. The drug demonstrated a 9.6 mmHg placebo-adjusted systolic blood pressure reduction in CKD patients and a 52.2% reduction in urinary albumin-to-creatinine ratio in those with baseline albuminuria, with a favorable safety profile. The drug is currently under FDA review with a PDUFA target date of December 22, 2026.

Mineralys Therapeutics presented clinical data for lorundrostat at ASN Kidney Week 2025, demonstrating promising results in reducing blood pressure and albuminuria in chronic kidney disease patients. The company plans to file a New Drug Application with the FDA in late 2025 or early 2026.

Two healthcare stocks, Precigen and Mineralys Therapeutics, have seen significant stock price increases recently due to FDA approval and promising clinical trial results in rare disease treatment and hypertension medication development.

Mineralys Therapeutics presented subgroup analyses from its Phase 3 Launch-HTN trial, demonstrating lorundrostat's efficacy in reducing blood pressure across diverse high-risk patient populations with uncontrolled hypertension, with consistent safety and meaningful clinical results.

Mineralys Therapeutics has priced a public offering of 9,803,921 shares at $25.50 per share, expecting to raise approximately $250 million to fund clinical development and corporate activities.

Mineralys Therapeutics announced positive results from the Phase 3 Launch-HTN trial of its drug lorundrostat for the treatment of uncontrolled or resistant hypertension. The trial demonstrated clinically meaningful and sustained reductions in systolic blood pressure with a favorable safety profile.